Italia markets closed

LNTH May 2024 52.500 call

OPR - OPR Prezzo differito. Valuta in USD.
Aggiungi a watchlist
24,000,00 (0,00%)
Alla chiusura: 10:38AM EDT
Schermo intero
Chiusura precedente24,00
Aperto24,00
Denaro26,10
Lettera29,20
Prezzo d'esercizio52,50
Scadenza2024-05-17
Min-Max giorno24,00 - 24,00
Contratto - Min-MaxN/D
Volume15
Open Interest28
  • GlobeNewswire

    Lantheus Announces Top Rated Oral Presentation Featuring PYLARIFY AI™ at the 2023 European Association of Nuclear Medicine (EANM) Annual Meeting

    BEDFORD, Mass., Sept. 01, 2023 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (the Company) (NASDAQ: LNTH), a company committed to improving patient outcomes through diagnostics, radiotherapeutics and artificial intelligence solutions that enable clinicians to Find, Fight and Follow disease, announced PYLARIFY AI data will be presented at the upcoming 2023 European Association of Nuclear Medicine (EANM) Annual Meeting, which will be held September 9-13, 2023 in Vienna, Austria. PYLARIFY AI™ (aPROMI

  • GlobeNewswire

    Lantheus to Present at the Wells Fargo Healthcare Conference

    BEDFORD, Mass., Aug. 31, 2023 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (“Lantheus”) (NASDAQ: LNTH), a company committed to improving patient outcomes through diagnostics, radiotherapeutics and artificial intelligence solutions that enable clinicians to Find, Fight and Follow disease, today announced Paul Blanchfield, President, and Bob Marshall, Chief Financial Officer and Treasurer, will present at the Wells Fargo Healthcare Conference at 9:30 a.m. ET on Thursday, September 7. To access a li

  • GlobeNewswire

    Lantheus Announces Agreement to Sell RELISTOR® Royalties to HealthCare Royalty

    Agreement enhances Lantheus’ strong liquidity position and supports continued pipeline advancement and commercial readinessBEDFORD, Mass., Aug. 03, 2023 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (“Lantheus” or the “Company”) (NASDAQ: LNTH), a company committed to improving patient outcomes through diagnostics, radiotherapeutics and artificial intelligence solutions that enable clinicians to Find, Fight and Follow disease, today announced the divestiture of its RELISTOR (methylnaltrexone bromid